Department of Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland.
Neuro Oncol. 2019 Feb 19;21(3):370-379. doi: 10.1093/neuonc/noy164.
We assessed population-level changes in glioblastoma survival between 2000 and 2013 in Finland, with focus on elderly patients (>70 y) in order to assess if changes in treatment of glioblastoma are reflected also in population-based survival rates.
We identified all patients (age ≥18 y) from the Finnish Cancer Registry (FCR) with a histopathological diagnosis of primary glioblastoma in 2000-2013. Patients were followed up until December 2015. The accuracy of register-based search of glioblastoma patients was internally validated. We report age-standardized relative survival ratios and relative excess risks (RERs) of death in 2000-2006 (pre-period) and 2007-2013 (post-period).
We identified 2045 glioblastoma patients from the FCR. The accuracy of the FCR-based search was 97%. Median age was 63.3 years, and 42% were women. Incidence increased on average by 1.6% (P = 0.004) and median age by 0.4 years per calendar year. Between the pre- and post-periods, the proportion of patients >70 years increased from 24% to 27%. In >70-year-old patients, the median survival time increased from 3.6 months in 2000-2006 to 4.5 months in 2007-2013 (RER 0.82, 95% CI: 0.68-0.98). In ≤70-year-old patients, the median survival time increased from 9.3 months in 2000-2006 to 11.7 months in 2007-2013 (RER 0.74, 95% CI: 0.67-0.82).
Despite the increased proportion of elderly glioblastoma patients, population-level survival of glioblastoma patients has improved since the year 2000. However, increasing incidence, increasing age of patients, and poor survival in elderly are alarming, and future studies should perhaps focus more on elderly.
我们评估了 2000 年至 2013 年芬兰胶质母细胞瘤患者的人群生存率变化,重点关注 70 岁以上的老年患者,以评估胶质母细胞瘤治疗方法的变化是否也反映在基于人群的生存率中。
我们从芬兰癌症登记处(FCR)中确定了所有在 2000 年至 2013 年间诊断为原发性胶质母细胞瘤的年龄≥18 岁的患者(FCR)。患者随访至 2015 年 12 月。对基于登记的胶质母细胞瘤患者的搜索进行了内部验证。我们报告了 2000-2006 年(前期)和 2007-2013 年(后期)的年龄标准化相对生存率比和死亡超额相对风险(RER)。
我们从 FCR 中确定了 2045 名胶质母细胞瘤患者。基于 FCR 的搜索准确率为 97%。中位年龄为 63.3 岁,42%为女性。发病率平均每年增加 1.6%(P=0.004),中位年龄每年增加 0.4 岁。在前期和后期之间,>70 岁的患者比例从 24%增加到 27%。在>70 岁的患者中,中位生存时间从 2000-2006 年的 3.6 个月增加到 2007-2013 年的 4.5 个月(RER 0.82,95%CI:0.68-0.98)。在≤70 岁的患者中,中位生存时间从 2000-2006 年的 9.3 个月增加到 2007-2013 年的 11.7 个月(RER 0.74,95%CI:0.67-0.82)。
尽管老年胶质母细胞瘤患者的比例增加,但自 2000 年以来,胶质母细胞瘤患者的人群生存率有所提高。然而,发病率的增加、患者年龄的增加以及老年患者的不良生存状况令人担忧,未来的研究或许应该更多地关注老年患者。